livemint.com
35%
230
Bharat Biotech, and 2 others tie up to develop 'variant-proof' COVID-19 vaccine
#bharatbiotech #sarscov2 #sarscov2vaccine #covid19 #covaxin #partnership pic.twitter.com/dMUnarqj8n With this new funding ExcellGene expands on a collaboration with the team of Prof Jamie Triccas that started in early 2020 Exe began to produce Wuhan trimerie SARS-Cav-spike proteins in March 2020, and nquendy Alpha, Beta, Delta and recently, Onicran variants. The Company delivered these antigens to its partners as highly purified stablised, trimeric spike proteins that had been angered for high-yield production, it said.